GAITHERSBURG, MD--(Marketwire - June 29, 2011) -
The founders of Noble Life Sciences announced today the formation of an investment capital fund called BlackRock BioCapital. BlackRock BioCapital will focus on creating and funding early stage technology-oriented biomedical companies developing novel therapeutic and diagnostic products.
The investment group will leverage the management and R&D infrastructure at Noble Life Sciences, a preclinical research services company. BlackRock BioCapital is actively seeking companies in which to invest as well as joint venture opportunities. The fund expects to make its first investment by the end of 2011.
Dr. Kenneth Carter, CEO of Noble Life Sciences and Managing Partner of BlackRock BioCapital, commented: "We are enthusiastic about the formation of BlackRock BioCapital and believe that this hybrid business model will accelerate product development through the flexible use of our R&D infrastructure. Moreover, BlackRock BioCapital will provide a base for shared-risk ventures with the institutional investment community and large pharmaceutical and biotechnology partners."
About BlackRock BioCapital, LLC:
BlackRock BioCapital, an investment capital group managed by the founders of Noble Life Sciences, is focused on funding early stage technology-oriented biomedical companies developing novel therapeutic and diagnostic products.
About Noble Life Sciences:
Noble Life Sciences provides a continuum of preclinical research services including preclinical experimental design and testing, disease models, selection and validation of biomarkers for personalized medicine, and vivarium services. With deep expertise in cancer drug development, the company offers access to their top scientists and works collaboratively with researchers in pharmaceutical, biotechnology, and diagnostic companies as well as those in academic and government institutions to deliver relevant, actionable information needed to expedite preclinical research and guide clinical development. For more information about Noble Life Sciences, visit www.noblelifesci.com.